Jacopo Nanni MD, Irene Azzali PhD, Cristina Papayannidis MD, PhD, Antonino Mulè MD, Ernesta Audisio MD, Maria Paola Martelli MD, PhD, Barbara Scappini MD, Patrizia Chiusolo MD, PhD, Benedetta Cambò MD, PhD, Anna Candoni MD, Monia Lunghi MD, Francesco Albano MD, PhD, Attilio Olivieri MD, Nicola Fracchiolla MD, Massimo Bernardi MD, Claudio Romani MD, Gian Matteo Rigolin MD, PhD, Maria Benedetta Giannini MD, Monica Bocchia MD, Elisabetta Todisco MD, Daniela Cilloni MD, PhD, Maria Teresa Bochicchio MSc, Emanuela Ottaviani MSc, Agnese Mattei MD, Federica Zamagni MSS, Irene Valli M.Sc. in PVRA, MPharm, Roberta Volpi MPharm, Giovanni Marconi MD, PhD, Elisabetta Petracci PhD, FLAM Collaborative Group, Giovanni Martinelli MD, PhD
{"title":"意大利FLT3突变AML患者（FLAM）队列研究的前期强化治疗分析：在现实生活中，FLT3抑制剂添加到标准化疗的影响","authors":"Jacopo Nanni MD, Irene Azzali PhD, Cristina Papayannidis MD, PhD, Antonino Mulè MD, Ernesta Audisio MD, Maria Paola Martelli MD, PhD, Barbara Scappini MD, Patrizia Chiusolo MD, PhD, Benedetta Cambò MD, PhD, Anna Candoni MD, Monia Lunghi MD, Francesco Albano MD, PhD, Attilio Olivieri MD, Nicola Fracchiolla MD, Massimo Bernardi MD, Claudio Romani MD, Gian Matteo Rigolin MD, PhD, Maria Benedetta Giannini MD, Monica Bocchia MD, Elisabetta Todisco MD, Daniela Cilloni MD, PhD, Maria Teresa Bochicchio MSc, Emanuela Ottaviani MSc, Agnese Mattei MD, Federica Zamagni MSS, Irene Valli M.Sc. in PVRA, MPharm, Roberta Volpi MPharm, Giovanni Marconi MD, PhD, Elisabetta Petracci PhD, FLAM Collaborative Group, Giovanni Martinelli MD, PhD","doi":"10.1002/cncr.35824","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with <i>FLT3</i>-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Clinical data are reported from 394 ND patients with <i>FLT3</i>-mutated AML enrolled in the retrospective observational Italian Cohort Study on <i>FLT3</i>-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, <i>n</i> = 92) or without (CT group, <i>n</i> = 302) the addition of a FLT3i.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, <i>p</i> < .01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, <i>p</i> = .01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, <i>p</i> = .052). FLT3i benefit seemed to be independent from the transplant rate.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 7","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35824","citationCount":"0","resultStr":"{\"title\":\"Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting\",\"authors\":\"Jacopo Nanni MD, Irene Azzali PhD, Cristina Papayannidis MD, PhD, Antonino Mulè MD, Ernesta Audisio MD, Maria Paola Martelli MD, PhD, Barbara Scappini MD, Patrizia Chiusolo MD, PhD, Benedetta Cambò MD, PhD, Anna Candoni MD, Monia Lunghi MD, Francesco Albano MD, PhD, Attilio Olivieri MD, Nicola Fracchiolla MD, Massimo Bernardi MD, Claudio Romani MD, Gian Matteo Rigolin MD, PhD, Maria Benedetta Giannini MD, Monica Bocchia MD, Elisabetta Todisco MD, Daniela Cilloni MD, PhD, Maria Teresa Bochicchio MSc, Emanuela Ottaviani MSc, Agnese Mattei MD, Federica Zamagni MSS, Irene Valli M.Sc. in PVRA, MPharm, Roberta Volpi MPharm, Giovanni Marconi MD, PhD, Elisabetta Petracci PhD, FLAM Collaborative Group, Giovanni Martinelli MD, PhD\",\"doi\":\"10.1002/cncr.35824\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with <i>FLT3</i>-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Clinical data are reported from 394 ND patients with <i>FLT3</i>-mutated AML enrolled in the retrospective observational Italian Cohort Study on <i>FLT3</i>-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, <i>n</i> = 92) or without (CT group, <i>n</i> = 302) the addition of a FLT3i.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, <i>p</i> < .01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, <i>p</i> = .01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, <i>p</i> = .052). FLT3i benefit seemed to be independent from the transplant rate.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.</p>\\n </section>\\n </div>\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":\"131 7\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35824\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35824\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35824","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting
Background
The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce.
Methods
Clinical data are reported from 394 ND patients with FLT3-mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n = 92) or without (CT group, n = 302) the addition of a FLT3i.
Results
With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p < .01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p = .01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p = .052). FLT3i benefit seemed to be independent from the transplant rate.
Conclusions
In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
